Leadership & Pay ·
Spero Therapeutics appoints William Ho as director following Patrick Vink's resignation
SPROSpero Therapeutics, Inc.
Patrick Vink resigned from the Board of Spero Therapeutics, Inc., effective November 10, 2026, citing no disputes. The company appointed William Ho, M.D., Ph.D., a physician-scientist and former Chief Medical Officer at RAPT Therapeutics, to fill the vacancy. Dr. Ho brings over 20 years of clinical development experience in oncology, allergy, and immunology, including work on programs that contributed to GSK's acquisition of RAPT Therapeutics. He will serve on the Development Committee and receive a $45,000 annual cash retainer plus stock options. Spero Therapeutics is a biopharmaceutical company focused on developing treatments for infectious diseases.